6660 — AIM Vaccine Share News
0.000.00%
Last trade - 00:00- HK$1.93bn
- HK$3.99bn
- CNY1.17bn
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Brief: AIM Vaccine Logs H1 Capex RMB 102.5 Mln
Brief: Aim Vaccine Says Approval For Clinical Trials In China And U.S. For Vaccine
Brief: Aim Vaccine Says Shaojun Jia Appointed As President
Brief: AIM Vaccine Says Serum-Free Iterative Rabies Vaccine Accepted For Market Registration By NMPA China
China's AIM Vaccine jumps on expectation of narrower annual loss
Brief: AIM Vaccine Sees FY Unaudited Revenue RMB1.25 Billion To RMB1.3 Billion
Brief: AIM Vaccine's Unit Obtains Production License For Serum-Free Rabies Vaccine
China's AIM Vaccine slumps on discounted share sale
Brief: Aim Vaccine Co Announces Placing Of 15.5 Million Shares
China's AIM jumps on approval of vaccine's clinical trial in US
Brief: AIM Vaccine Says Clinical Trial Of MRNA Respiratory Syncytial Virus Vaccines Approved By FDA
Brief: AIM Vaccine Says Fully Integrates Deepseek In All Business Scenarios
China's AIM jumps on vaccine's clinical trial application in US
Brief: AIM Vaccine Says Second Generation Of Absorbed Tetanus Vaccine Obtained Clinical Trial Approval
Brief: AIM Vaccine Says Suspension Culture Influenza Vaccine (MDCK Cells) Got Clinical Trial Approval